Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q1FY25) ended June 30, 2024.
Financial Highlights (In ₹ m)
Particulars | Q1FY25 | Q1FY24 | YoY | Q4FY24 | QoQ |
Revenues | 10,875 | 9,320 | 16.7% | 10,583 | 2.8% |
Gross Margin | 6,671 | 5,470 | 21.9% | 6,421 | 3.9% |
Gross Margin % | 61.3% | 58.7% | 264bps | 60.7% | 67bps |
EBITDA | 2,170 | 1,686 | 28.7% | 2,040 | 6.4% |
EBITDA % | 20.0% | 18.1% | 187bps | 19.3% | 68bps |
Adj PAT | 839 | 295 |
| 670 |
|
Reported PAT | 683 | (94) |
| 104 |
|
Adjusted PAT = PAT from continuing operations without JV share and exceptional items
Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, "Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook.
The company achieved critical thresholds of 20% EBITDA margin, ₹683m of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business.
The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes."
